BR112019024667A2 - Uso de um agente bioativo, e, de uma composição - Google Patents

Uso de um agente bioativo, e, de uma composição Download PDF

Info

Publication number
BR112019024667A2
BR112019024667A2 BR112019024667-3A BR112019024667A BR112019024667A2 BR 112019024667 A2 BR112019024667 A2 BR 112019024667A2 BR 112019024667 A BR112019024667 A BR 112019024667A BR 112019024667 A2 BR112019024667 A2 BR 112019024667A2
Authority
BR
Brazil
Prior art keywords
bioactive agent
composition
activity
increases
treatment
Prior art date
Application number
BR112019024667-3A
Other languages
English (en)
Inventor
Kirkegaard Jensen Thomas
Greensmith Linda
Original Assignee
Orphazyme A/S
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphazyme A/S, Ucl Business Plc filed Critical Orphazyme A/S
Publication of BR112019024667A2 publication Critical patent/BR112019024667A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a um agente bioativo que aumenta a concentração intracelular e/ou a atividade de uma ou mais proteínas de choque térmico, incluindo hsp70, para uso no tratamento de distúrbios frontotemporais.
BR112019024667-3A 2017-05-24 2018-05-24 Uso de um agente bioativo, e, de uma composição BR112019024667A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172669.8 2017-05-24
EP17172669 2017-05-24
PCT/EP2018/063662 WO2018215597A1 (en) 2017-05-24 2018-05-24 Heat shock protein inducers and frontotemporal disorders

Publications (1)

Publication Number Publication Date
BR112019024667A2 true BR112019024667A2 (pt) 2020-06-16

Family

ID=59021239

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019024667-3A BR112019024667A2 (pt) 2017-05-24 2018-05-24 Uso de um agente bioativo, e, de uma composição

Country Status (11)

Country Link
US (1) US20200085812A1 (pt)
EP (1) EP3630105A1 (pt)
JP (1) JP2020520947A (pt)
CN (1) CN110753544A (pt)
AU (1) AU2018274176A1 (pt)
BR (1) BR112019024667A2 (pt)
CA (1) CA3063974A1 (pt)
IL (1) IL270746A (pt)
MX (1) MX2019013835A (pt)
RU (1) RU2019141123A (pt)
WO (1) WO2018215597A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922242A1 (en) 2014-09-15 2021-12-15 Orphazyme A/S Arimoclomol formulation
EP3820494A4 (en) * 2018-07-13 2022-07-13 The Trustees of Princeton University SYSTEM AND METHOD FOR MODULATING THE ASSEMBLY OF STRESS PELLETS
CA3156060A1 (en) 2019-09-27 2021-04-01 Takeda Pharmaceutical Company Limited 2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS
JP2021187789A (ja) * 2020-06-01 2021-12-13 株式会社リアルメイト ヒートショックプロテイン誘導剤、一酸化窒素産生促進剤、抗更年期障害剤、抗加齢剤、化粧品および食品または飲料

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HU226617B1 (en) 1998-12-14 2009-04-28 Cytrx Corp Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0303584A3 (en) 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
US20130209549A1 (en) * 2010-07-21 2013-08-15 University Of South Florida Materials and methods for treating neurodegenerative diseases
WO2013006076A1 (en) * 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases

Also Published As

Publication number Publication date
CN110753544A (zh) 2020-02-04
IL270746A (en) 2020-01-30
CA3063974A1 (en) 2018-11-29
RU2019141123A3 (pt) 2021-09-10
AU2018274176A1 (en) 2020-01-16
MX2019013835A (es) 2020-07-14
WO2018215597A1 (en) 2018-11-29
EP3630105A1 (en) 2020-04-08
JP2020520947A (ja) 2020-07-16
US20200085812A1 (en) 2020-03-19
RU2019141123A (ru) 2021-06-24

Similar Documents

Publication Publication Date Title
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
BR112019024667A2 (pt) Uso de um agente bioativo, e, de uma composição
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
EA201692109A1 (ru) Варианты антител к фактору d и их применение
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
BR112015029611A2 (pt) composições para uso em ruptura de cartilagem
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112016024691A2 (pt) ciclo-hexanocarboxamida com propriedades de resfriamento
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CL2018003383A1 (es) Proteínas f de prefusión del vrs estabilizadas.
CY1124596T1 (el) Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112018001435A2 (pt) métodos para entrega linfática de agentes ativos
BR112017017970A2 (pt) composição de fragrância e combinação de fragrâncias
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements